Redefining stage i endometrial cancer: Incorporating histology, a binary grading system, myometrial invasion, and lymph node assessment

International Journal of Gynecological Cancer

Volumn 23, Issue 9, 2013, Pages 1620-1628

  Barlin, Joyce N ^a   Soslow, Robert A ^a   Lutz, Megan ^a   Zhou, Qin C ^a   St Clair, Caryn M ^a   Leitao Jr , Mario M ^a,b   Iasonos, Alexia ^a   Hensley, Martee L ^a   Barakat, Richard R ^a,b   Matias Guiu, Xavier ^c   Abu Rustum, Nadeem R ^a,b  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

^c HOSPITAL UNIVERSITARI ARNAU DE VILANOVA   (Spain)

Author keywords

Endometrial cancer; FIGO; Stage I

Indexed keywords

ADULT; AGE DISTRIBUTION; ARTICLE; CANCER STAGING; CANCER SURVIVAL; CARCINOSARCOMA; CLEAR CELL CARCINOMA; ENDOMETRIOID CARCINOMA; ENDOMETRIUM CANCER; ENDOMETRIUM CARCINOMA; FEMALE; FOLLOW UP; HISTOLOGY; HUMAN; LYMPH NODE; MAJOR CLINICAL STUDY; OVERALL SURVIVAL; PRACTICE GUIDELINE; PRIORITY JOURNAL; REFERENCE DATABASE; TUMOR INVASION;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, ENDOMETRIOID; ENDOMETRIAL NEOPLASMS; FEMALE; FOLLOW-UP STUDIES; HUMANS; LYMPH NODES; LYMPHATIC METASTASIS; MIDDLE AGED; MYOMETRIUM; NEOPLASM GRADING; NEOPLASM INVASIVENESS; NEOPLASM STAGING; SURVIVAL ANALYSIS;

EID: 84888383863     PISSN: 1048891X     EISSN: 15251438     Source Type: Journal    
DOI: 10.1097/IGC.0b013e3182a5055e     Document Type: Article

References (27)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin. 2012; 62: 10-29.
2. Boronow RC, Morrow CP, Creasman WT, et al. Surgical staging in endometrial cancer: clinical-pathologic findings of a prospective study. Obstet Gynecol. 1984; 63: 825-832.
3. Creasman WT, Morrow CP, Bundy BN, et al. Surgical pathologic spread patterns of endometrial cancer. A Gynecologic Oncology Group Study. Cancer. 1987; 60: 2035-2041.
4. Pecorelli S. Revised FIGO staging for carcinoma of the vulva, cervix, and endometrium. Int J Gynaecol Obstet. 2009; 105: 103-104.
5. Cancer Genome Atlas Research Network, Kandoth C, Schultz N, et al. Integrated genomic characterization of endometrial carcinoma. Nature. 2013; 497: 67-73.
6. Gonen M, Heller G. Concordance probability and discriminatory power in proportional hazards regression. Biometrika. 2005; 92: 965-970.
7. Harrell FE Jr, Lee KL, Mark DB. Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med. 1996; 15: 361-387.
8. Benedet JL, Pecorelli S. Why cancer staging? FIGO 26th annual report on the results of treatment in gynecological cancer. Int J Gynaecol Obstet. 2006; 95:S3.
9. Odicino F, Pecorelli S, Zigliani L, et al. History of the FIGO cancer staging system. Int J Gynecol Obstet. 2009; 101: 205-210.
10. Abu-Rustum NR, Zhou Q, Iasonos A, et al. The revised 2009 FIGO staging system for endometrial cancer: should the 1988 FIGO stages IA and IB be altered? Int J Gynecol Cancer. 2011; 21: 511-516.
11. DiSaia PJ, Creasman WT, Boronow RC, et al. Risk factors and recurrent patterns in stage I endometrial carcinoma. Am J Obstet Gynecol. 1984; 151: 1009-1015.
12. Bokhman JV. Two pathogenetic types of endometrial carcinoma. Gynecol Oncol. 1983; 15: 10-17.
13. Mhawech-Fauceglia P, Yan L, Liu S, et al. ER /PR /TFF3 /IMP3 immunoprofile distinguishes endometrioid from serous and clear cell carcinomas of the endometrium: a study of 401 cases. Histopathology. 2013; 62: 976-985.
14. Paik D, Cocco E, Bellone S, et al. Higher sensitivity to patupilone versus paclitaxel chemotherapy in primary uterine serous papillary carcinoma cell lines with high versus low HER-2/neu expression in vitro. Gynecol Oncol. 2010; 119: 140-145.
15. Kelly MG, O'Malley DM, Hui P, et al. Improved survival in surgical stage I patients with uterine papillary serous carcinoma (UPSC) treated with adjuvant platinum-based chemotherapy. Gynecol Oncol. 2005; 98: 353-359.
16. Winer I, Mahdi H, Bandyopadhyay S, et al. Correlation of tumor size with other prognostic factors in uterine serous carcinoma: a large multi-institutional study. Gynecol Oncol. 2013; 128: 316-321.
17. Seward S, Ali-Fehmi R, Munkarah AR, et al. Outcomes of patients with uterine serous carcinoma using the revised FIGO staging system. Int J Gynecol Cancer. 2012; 22: 452-456.
18. Ayeni TA, Bakkum-Gamez JN, Mariani A, et al. Comparative outcomes assessment of uterine grade 3 endometrioid, serous, and clear cell carcinomas. Gynecol Oncol. 2013; 128: 71-76.
19. Soslow RA, Bissonnette JP, Wilton A, et al. Clinicopathologic analysis of 187 high-grade endometrial carcinomas of different histologic subtypes: similar outcomes belie distinctive biologic differences. Am J Surg Pathol. 2007; 31: 979-987.
20. Alektiar KM, McKee A, Lin O, et al. Is there a difference in outcome between stage I-II endometrial cancer of papillary serous/clear cell and endometrioid FIGO Grade 3 cancer? Int J Radiat Oncol Biol Phys. 2002; 54: 79-85.
21. Creasman WT. The current status of lymphadenectomy in the management of endometrial cancer. Womens Health (Lond Engl). 2011; 7: 33-35.
22. Benedetti Panici P, Basile S, Maneschi F, et al. Systematic pelvic lymphadenectomy vs. no lymphadenectomy in early-stage endometrial carcinoma: randomized clinical trial. J Natl Cancer Inst. 2008; 100: 1707-1716.
23. ASTEC Study Group, Kitchener H, Swart AM, et al. Efficacy of systematic pelvic lymphadenectomy in endometrial cancer (MRC ASTEC trial): a randomised study. Lancet. 2009; 373: 125-136.
24. Barlin JN, Khoury-Collado F, Kim CH, et al. The importance of applying a sentinel lymph node mapping algorithm in endometrial cancer staging: beyond removal of blue nodes. Gynecol Oncol. 2012; 125: 531-535.
25. Khoury-Collado F, Murray MP, Hensley ML, et al. Sentinel lymph node mapping for endometrial cancer improves the detection of metastatic disease to regional lymph nodes. Gynecol Oncol. 2011; 122: 251-254.
26. Cormier B, Sauthier P, Lussier C, et al. Determinants of lymph node count in endometrial cancer surgical staging. Int J Gynecol Cancer. 2012; 22: 1361-1366.
27. Abu-Rustum NR, Iasonos A, Zhou Q, et al. Is there a therapeutic impact to regional lymphadenectomy in the surgical treatment of endometrial carcinoma? Am J Obstet Gynecol. 2008; 198:457.e1-457.e5; discussion 457.e5-457.e6.